Researchers at the Pennington Biomedical Research Center conducted a first-of-its-kind study to provide insights into the ...

Fridays weight loss is a telehealth provider that offers access to popular GLP-1 medications, including compounded versions ...

Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S.

Adults with overweight or obesity plus prediabetes maintain most of their weight loss with tirzepatide at more than 3 years, ...

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...

A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...

Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and ...

As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

In December 2024, the FDA affirmed that the shortage of tirzepatide, marketed as Zepbound for weight loss, had ended, ...

Shares in pharmaceuticals firm Eli Lilly (LLY) rose today after it said it was suing companies ripping off its weight-loss ...